Stocks · News reference
Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $16 price target.
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly gains positive CHMP opinion for Foundayo (orforglipron), a new oral GLP-1 tablet for weight loss and type 2 diabetes.
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.